Current Opinion in Hematology volume 19, issue 3, P141-148 2012 DOI: 10.1097/moh.0b013e328351c348 View full text
|
|
Share
Charles J. Parker

Abstract: Long-term safety and efficacy of eculizumab was observed in a large group of patients. Survival for the group was not different from that of a sex-matched and age-matched control group from the general population. Thrombotic complications were rare and deaths due to PNH or complications of therapy were not observed. These studies suggest that patients with clinical PNH who are treated with eculizumab have a benign clinical course. Patients with bone marrow failure who have PNH cells detected by high-sensitivit…

expand abstract